[Skip to Content]
[Skip to Content Landing]

Surgical Management of Gastric CancerA Review

Educational Objective
To identify the key insights or developments described in this article
1 Credit CME
Abstract

Importance  Surgery plays a critical role in the management of all stages of gastric cancer.

Observations  For patients with early gastric cancer and low risk of lymph node metastasis, endoscopic therapy or surgery alone is potentially curative. Novel techniques, such as sentinel lymph node biopsy, may allow for greater use of stomach-sparing procedures that could improve quality of life without compromising oncologic outcomes; however, experience with these techniques is rare outside of East Asia, and studies of long-term outcomes are still ongoing. Patients with later-stage localized gastric cancer benefit from more extensive lymphadenectomy and multimodality therapy, as they are at risk for nodal and distant metastases. There have been recent advances in chemotherapy that have led to improved survival, but the optimal sequencing of multimodality therapy is still being investigated. Better systemic therapy may also increase the role of surgery for patients with oligometastatic disease. There are ongoing studies examining the efficacy of peritoneal-directed therapies in both patients with low-volume peritoneal disease and patients at high risk of peritoneal recurrence.

Conclusions and Relevance  The management of gastric cancer continues to evolve. Surgeons should be aware of novel surgical approaches currently under investigation as well as how surgery fits into the contemporary multidisciplinary approach to this disease.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Accepted for Publication: December 19, 2021.

Published Online: March 23, 2022. doi:10.1001/jamasurg.2022.0182

Corresponding Author: Jiping Wang, MD, PhD, Department of Surgery, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115 (jwang39@bwh.harvard.edu).

Author Contributions: Dr Wang had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: All authors.

Acquisition, analysis, or interpretation of data: Wang.

Drafting of the manuscript: Li, Wang.

Critical revision of the manuscript for important intellectual content: All authors.

Administrative, technical, or material support: Doherty, Wang.

Supervision: Doherty, Wang.

Conflict of Interest Disclosures: None reported.

References
1.
Coggon  D , Barker  DJ , Cole  RB , Nelson  M .  Stomach cancer and food storage.   J Natl Cancer Inst. 1989;81(15):1178-1182. doi:10.1093/jnci/81.15.1178PubMedGoogle ScholarCrossref
2.
Parsonnet  J , Vandersteen  D , Goates  J , Sibley  RK , Pritikin  J , Chang  Y .  Helicobacter pylori infection in intestinal- and diffuse-type gastric adenocarcinomas.   J Natl Cancer Inst. 1991;83(9):640-643. doi:10.1093/jnci/83.9.640PubMedGoogle ScholarCrossref
3.
Wanebo  HJ , Kennedy  BJ , Chmiel  J , Steele  G  Jr , Winchester  D , Osteen  R .  Cancer of the stomach. a patient care study by the American College of Surgeons.   Ann Surg. 1993;218(5):583-592. doi:10.1097/00000658-199321850-00002PubMedGoogle ScholarCrossref
4.
Bray  F , Ferlay  J , Soerjomataram  I , Siegel  RL , Torre  LA , Jemal  A .  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.   CA Cancer J Clin. 2018;68(6):394-424. doi:10.3322/caac.21492PubMedGoogle ScholarCrossref
5.
Siegel  RL , Miller  KD , Jemal  A .  Cancer statistics, 2019.   CA Cancer J Clin. 2019;69(1):7-34. doi:10.3322/caac.21551PubMedGoogle ScholarCrossref
6.
Van Cutsem  E , Sagaert  X , Topal  B , Haustermans  K , Prenen  H .  Gastric cancer.   Lancet. 2016;388(10060):2654-2664. doi:10.1016/S0140-6736(16)30354-3PubMedGoogle ScholarCrossref
7.
Abdelfatah  MM , Barakat  M , Lee  H ,  et al.  The incidence of lymph node metastasis in early gastric cancer according to the expanded criteria in comparison with the absolute criteria of the Japanese Gastric Cancer Association: a systematic review of the literature and meta-analysis.   Gastrointest Endosc. 2018;87(2):338-347. doi:10.1016/j.gie.2017.09.025PubMedGoogle ScholarCrossref
8.
Kamarajah  SK , Markar  SR , Phillips  AW , Salti  GI , Dahdaleh  FS .  Local endoscopic resection is inferior to gastrectomy for early clinical stage T1a and T1b gastric adenocarcinoma: a propensity-matched study.   Ann Surg Oncol. 2021;28(6):2992-2998. doi:10.1245/s10434-020-09485-4PubMedGoogle ScholarCrossref
9.
Manner  H , Rabenstein  T , May  A ,  et al.  Long-term results of endoscopic resection in early gastric cancer: the Western experience.   Am J Gastroenterol. 2009;104(3):566-573.PubMedGoogle Scholar
10.
Uedo  N , Iishi  H , Tatsuta  M ,  et al.  Long-term outcomes after endoscopic mucosal resection for early gastric cancer.   Gastric Cancer. 2006;9(2):88-92. doi:10.1007/s10120-005-0357-0PubMedGoogle ScholarCrossref
11.
Japanese Gastric Cancer Association.  Japanese Gastric Cancer Treatment Guidelines 2014 (ver. 4).   Gastric Cancer. 2017;20(1):1-19. doi:10.1007/s10120-016-0622-4PubMedGoogle ScholarCrossref
12.
Smyth  EC , Verheij  M , Allum  W , Cunningham  D , Cervantes  A , Arnold  D ; ESMO Guidelines Committee.  Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up.   Ann Oncol. 2016;27(suppl 5):v38-v49. doi:10.1093/annonc/mdw350PubMedGoogle ScholarCrossref
13.
Ajani  JA , D’Amico  TA , Bentrem  DJ ,  et al.  Esophageal and esophagogastric junction cancers, version 2.2021, NCCN clinical practice guidelines oncology.   J Natl Compr Canc Netw. 2019;17(7):855-883.doi:10.6004/jnccn.2019.0033PubMedGoogle ScholarCrossref
14.
Fukase  K , Kato  M , Kikuchi  S ,  et al; Japan Gast Study Group.  Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial.   Lancet. 2008;372(9636):392-397. doi:10.1016/S0140-6736(08)61159-9PubMedGoogle ScholarCrossref
15.
Bausys  R , Bausys  A , Vysniauskaite  I ,  et al.  Risk factors for lymph node metastasis in early gastric cancer patients: report from Eastern Europe country—Lithuania.   BMC Surg. 2017;17(1):108. doi:10.1186/s12893-017-0304-0PubMedGoogle ScholarCrossref
16.
Jung  DH , Huh  CW , Kim  J-H ,  et al.  Risk-stratification model based on lymph node metastasis after noncurative endoscopic resection for early gastric cancer.   Ann Surg Oncol. 2017;24(6):1643-1649. doi:10.1245/s10434-017-5791-9PubMedGoogle ScholarCrossref
17.
Takeuchi  H , Kitagawa  Y .  Sentinel lymph node biopsy in gastric cancer.   Cancer J. 2015;21(1):21-24. doi:10.1097/PPO.0000000000000088PubMedGoogle ScholarCrossref
18.
Miyashiro  I , Hiratsuka  M , Sasako  M ,  et al; Gastric Cancer Surgical Study Group (GCSSG) in the Japan Clinical Oncology Group (JCOG).  High false-negative proportion of intraoperative histological examination as a serious problem for clinical application of sentinel node biopsy for early gastric cancer: final results of the Japan Clinical Oncology Group multicenter trial JCOG0302.   Gastric Cancer. 2014;17(2):316-323. doi:10.1007/s10120-013-0285-3PubMedGoogle ScholarCrossref
19.
Kitagawa  Y , Takeuchi  H , Takagi  Y ,  et al.  Sentinel node mapping for gastric cancer: a prospective multicenter trial in Japan.   J Clin Oncol. 2013;31(29):3704-3710. doi:10.1200/JCO.2013.50.3789PubMedGoogle ScholarCrossref
20.
Ryu  KW , Eom  BW , Nam  B-H ,  et al.  Is the sentinel node biopsy clinically applicable for limited lymphadenectomy and modified gastric resection in gastric cancer? a meta-analysis of feasibility studies.   J Surg Oncol. 2011;104(6):578-584. doi:10.1002/jso.21995PubMedGoogle ScholarCrossref
21.
Park  JY , Kim  Y-W , Ryu  KW ,  et al.  Assessment of laparoscopic stomach preserving surgery with sentinel basin dissection versus standard gastrectomy with lymphadenectomy in early gastric cancer—a multicenter randomized phase III clinical trial (SENORITA trial) protocol.   BMC Cancer. 2016;16:340. doi:10.1186/s12885-016-2336-8PubMedGoogle ScholarCrossref
22.
Slagter  AE , Jansen  EPM , van Laarhoven  HWM ,  et al.  CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery vs neoadjuvant chemoradiotherapy followed by surgery in resectable gastric cancer.   BMC Cancer. 2018;18(1):877. doi:10.1186/s12885-018-4770-2PubMedGoogle ScholarCrossref
23.
Leong  T , Smithers  BM , Haustermans  K ,  et al.  TOPGEAR: a randomized, phase III trial of perioperative ECF chemotherapy with or without preoperative chemoradiation for resectable gastric cancer: interim results from an international, intergroup trial of the AGITG, TROG, EORTC, and CCTG.   Ann Surg Oncol. 2017;24(8):2252-2258. doi:10.1245/s10434-017-5830-6PubMedGoogle ScholarCrossref
24.
Cui  S-Z , Liang  H , Li  Y ,  et al; Chinese Peritoneal Oncology Study Group.  PILGRIM: Phase III Clinical Trial in Evaluating the Role of Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Gastric Cancer Patients After Radical Gastrectomy With D2 Lymphadenectomy (HIPEC-01).   J Clin Oncol. 2020;38(15):4538. doi:10.1200/JCO.2020.38.15_suppl.4538Google ScholarCrossref
25.
Al-Batran  SE , Goetze  TO , Mueller  DW ,  et al.  The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction—a phase III trial of the German AIO/CAO-V/CAOGI.   BMC Cancer. 2017;17(1):893. doi:10.1186/s12885-017-3918-9PubMedGoogle ScholarCrossref
26.
Furukawa  H , Hiratsuka  M , Imaoka  S ,  et al.  Phase II study of limited surgery for early gastric cancer: segmental gastric resection.   Ann Surg Oncol. 1999;6(2):166-170. doi:10.1007/s10434-999-0166-5PubMedGoogle ScholarCrossref
27.
Isozaki  H , Matsumoto  S , Murakami  S ,  et al.  Diminished gastric resection preserves better quality of life in patients with early gastric cancer.   Acta Med Okayama. 2016;70(2):119-130.PubMedGoogle Scholar
28.
Abe  N , Takeuchi  H , Ohki  A ,  et al.  Long-term outcomes of combination of endoscopic submucosal dissection and laparoscopic lymph node dissection without gastrectomy for early gastric cancer patients who have a potential risk of lymph node metastasis.   Gastrointest Endosc. 2011;74(4):792-797. doi:10.1016/j.gie.2011.06.006PubMedGoogle ScholarCrossref
29.
Zhao  L , Ling  R , Chen  J ,  et al.  Clinical outcomes of proximal gastrectomy versus total gastrectomy for proximal gastric cancer: a systematic review and meta-analysis.   Dig Surg. 2021;38(1):1-13. doi:10.1159/000506104PubMedGoogle ScholarCrossref
30.
Japanese Gastric Cancer Association.  Japanese classification of gastric carcinoma: 3rd English edition.   Gastric Cancer. 2011;14(2):101-112. doi:10.1007/s10120-011-0041-5PubMedGoogle ScholarCrossref
31.
Cuschieri  A , Fayers  P , Fielding  J ,  et al.  Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. the Surgical Cooperative Group.   Lancet. 1996;347(9007):995-999. doi:10.1016/S0140-6736(96)90144-0PubMedGoogle ScholarCrossref
32.
Cuschieri  A , Weeden  S , Fielding  J ,  et al; Surgical Co-operative Group.  Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial.   Br J Cancer. 1999;79(9-10):1522-1530. doi:10.1038/sj.bjc.6690243PubMedGoogle ScholarCrossref
33.
Bonenkamp  JJ , Hermans  J , Sasako  M ,  et al; Dutch Gastric Cancer Group.  Extended lymph-node dissection for gastric cancer.   N Engl J Med. 1999;340(12):908-914. doi:10.1056/NEJM199903253401202PubMedGoogle ScholarCrossref
34.
Songun  I , Putter  H , Kranenbarg  EM , Sasako  M , van de Velde  CJ .  Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial.   Lancet Oncol. 2010;11(5):439-449. doi:10.1016/S1470-2045(10)70070-XPubMedGoogle ScholarCrossref
35.
Dikken  JL , Jansen  EP , Cats  A ,  et al.  Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer.   J Clin Oncol. 2010;28(14):2430-2436. doi:10.1200/JCO.2009.26.9654PubMedGoogle ScholarCrossref
36.
Woo  Y , Goldner  B , Son  T ,  et al.  Western validation of a novel gastric cancer prognosis prediction model in US gastric cancer patients.   J Am Coll Surg. 2018;226(3):252-258. doi:10.1016/j.jamcollsurg.2017.12.016PubMedGoogle ScholarCrossref
37.
Wang  J .  The winner for D2 lymph node dissection in distal gastrectomy—anatomic landmarks vs number of examined lymph nodes.   Art Surg. Published online December 19, 2017. doi:10.21037/aos.2017.11.07Google ScholarCrossref
38.
Sano  T , Sasako  M , Yamamoto  S ,  et al.  Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy—Japan Clinical Oncology Group study 9501.   J Clin Oncol. 2004;22(14):2767-2773. doi:10.1200/JCO.2004.10.184PubMedGoogle ScholarCrossref
39.
Hyung  WJ , Yang  H-K , Park  Y-K ,  et al; Korean Laparoendoscopic Gastrointestinal Surgery Study Group.  Long-term outcomes of laparoscopic distal gastrectomy for locally advanced gastric cancer: the KLASS-02-RCT randomized clinical trial.   J Clin Oncol. 2020;38(28):3304-3313. doi:10.1200/JCO.20.01210PubMedGoogle ScholarCrossref
40.
Kim  W , Kim  H-H , Han  S-U ,  et al; Korean Laparo-endoscopic Gastrointestinal Surgery Study (KLASS) Group.  Decreased morbidity of laparoscopic distal gastrectomy compared with open distal gastrectomy for stage I gastric cancer: short-term outcomes from a multicenter randomized controlled trial (KLASS-01).   Ann Surg. 2016;263(1):28-35. doi:10.1097/SLA.0000000000001346PubMedGoogle ScholarCrossref
41.
Yu  J , Huang  C , Sun  Y ,  et al; Chinese Laparoscopic Gastrointestinal Surgery Study (CLASS) Group.  Effect of laparoscopic vs open distal gastrectomy on 3-year disease-free survival in patients with locally advanced gastric cancer: the CLASS-01 randomized clinical trial.   JAMA. 2019;321(20):1983-1992. doi:10.1001/jama.2019.5359PubMedGoogle ScholarCrossref
42.
Kelly  KJ , Selby  L , Chou  JF ,  et al.  Laparoscopic versus open gastrectomy for gastric adenocarcinoma in the West: a case-control study.   Ann Surg Oncol. 2015;22(11):3590-3596. doi:10.1245/s10434-015-4381-yPubMedGoogle ScholarCrossref
43.
van der Veen  A , Brenkman  HJF , Seesing  MFJ ,  et al; LOGICA Study Group.  Laparoscopic Versus Open Gastrectomy for Gastric Cancer (LOGICA): a multicenter randomized clinical trial.   J Clin Oncol. 2021;39(9):978-989. doi:10.1200/JCO.20.01540PubMedGoogle ScholarCrossref
44.
Kim  H-G , Park  J-H , Jeong  S-H ,  et al.  Totally laparoscopic distal gastrectomy after learning curve completion: comparison with laparoscopy-assisted distal gastrectomy.   J Gastric Cancer. 2013;13(1):26-33. doi:10.5230/jgc.2013.13.1.26PubMedGoogle ScholarCrossref
45.
Jung  DH , Son  S-Y , Park  YS ,  et al.  The learning curve associated with laparoscopic total gastrectomy.   Gastric Cancer. 2016;19(1):264-272. doi:10.1007/s10120-014-0447-yPubMedGoogle ScholarCrossref
46.
Kim  H-I , Han  S-U , Yang  H-K ,  et al.  Multicenter prospective comparative study of robotic versus laparoscopic gastrectomy for gastric adenocarcinoma.   Ann Surg. 2016;263(1):103-109. doi:10.1097/SLA.0000000000001249PubMedGoogle ScholarCrossref
47.
Li  Z-Y , Zhou  Y-B , Li  T-Y ,  et al; Robotic, Laparoscopic Surgery Committee of Chinese Research Hospital Association.  Robotic gastrectomy vs laparoscopic gastrectomy for gastric cancer: a multicenter cohort study of 5402 patients in China.   Ann Surg. 2021. doi:10.1097/SLA.0000000000005046PubMedGoogle ScholarCrossref
48.
Kim  MS , Kim  WJ , Hyung  WJ ,  et al.  Comprehensive learning curve of robotic surgery: discovery from a multicenter prospective trial of robotic gastrectomy.   Ann Surg. 2021;273(5):949-956. doi:10.1097/SLA.0000000000003583PubMedGoogle ScholarCrossref
49.
Strong  VE , Russo  AE , Nakauchi  M ,  et al.  Robotic gastrectomy for gastric adenocarcinoma in the USA: insights and oncologic outcomes in 220 patients.   Ann Surg Oncol. 2021;28(2):742-750. doi:10.1245/s10434-020-08834-7PubMedGoogle ScholarCrossref
50.
Cunningham  D , Allum  WH , Stenning  SP ,  et al; MAGIC Trial Participants.  Perioperative chemotherapy vs surgery alone for resectable gastroesophageal cancer.   N Engl J Med. 2006;355(1):11-20. doi:10.1056/NEJMoa055531PubMedGoogle ScholarCrossref
51.
Al-Batran  SE , Homann  N , Pauligk  C ,  et al; FLOT4-AIO Investigators.  Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.   Lancet. 2019;393(10184):1948-1957. doi:10.1016/S0140-6736(18)32557-1PubMedGoogle ScholarCrossref
52.
Cats  A , Jansen  EPM , van Grieken  NCT ,  et al; CRITICS investigators.  Chemotherapy vs chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.   Lancet Oncol. 2018;19(5):616-628. doi:10.1016/S1470-2045(18)30132-3PubMedGoogle ScholarCrossref
53.
Rivera  F , Izquierdo-Manuel  M , García-Alfonso  P ,  et al.  Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial.   Eur J Cancer. 2021;145:158-167. doi:10.1016/j.ejca.2020.12.005PubMedGoogle ScholarCrossref
54.
Shitara  K , Van Cutsem  E , Bang  YJ ,  et al.  Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial.   JAMA Oncol. 2020;6(10):1571-1580. doi:10.1001/jamaoncol.2020.3370PubMedGoogle ScholarCrossref
55.
Ajani  JA , Winter  K , Okawara  GS ,  et al.  Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response.   J Clin Oncol. 2006;24(24):3953-3958. doi:10.1200/JCO.2006.06.4840PubMedGoogle ScholarCrossref
56.
Bang  Y-J , Kim  Y-W , Yang  H-K ,  et al; CLASSIC trial investigators.  Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.   Lancet. 2012;379(9813):315-321. doi:10.1016/S0140-6736(11)61873-4PubMedGoogle ScholarCrossref
57.
Noh  SH , Park  SR , Yang  H-K ,  et al; CLASSIC trial investigators.  Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.   Lancet Oncol. 2014;15(12):1389-1396. doi:10.1016/S1470-2045(14)70473-5PubMedGoogle ScholarCrossref
58.
Sasako  M , Sakuramoto  S , Katai  H ,  et al.  Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 vs surgery alone in stage II or III gastric cancer.   J Clin Oncol. 2011;29(33):4387-4393. doi:10.1200/JCO.2011.36.5908PubMedGoogle ScholarCrossref
59.
Macdonald  JS , Smalley  SR , Benedetti  J ,  et al.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.   N Engl J Med. 2001;345(10):725-730. doi:10.1056/NEJMoa010187PubMedGoogle ScholarCrossref
60.
Park  SH , Sohn  TS , Lee  J ,  et al.  Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin vs concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses.   J Clin Oncol. 2015;33(28):3130-3136. doi:10.1200/JCO.2014.58.3930PubMedGoogle ScholarCrossref
61.
Park  SH , Lim  DH , Sohn  TS ,  et al; ARTIST 2 investigators.  A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial.   Ann Oncol. 2021;32(3):368-374. doi:10.1016/j.annonc.2020.11.017PubMedGoogle ScholarCrossref
62.
Yang  TS , Wang  XF , Fairweather  M , Sun  YH , Mamon  HJ , Wang  JP .  The survival benefit from the addition of radiation to chemotherapy in gastric cancer patients following surgical resection.   Clin Oncol (R Coll Radiol). 2020;32(2):110-120. doi:10.1016/j.clon.2019.09.047PubMedGoogle ScholarCrossref
63.
Stiekema  J , Trip  AK , Jansen  EP ,  et al.  The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy.   Ann Surg Oncol. 2014;21(4):1107-1114. doi:10.1245/s10434-013-3397-4PubMedGoogle ScholarCrossref
64.
Al-Batran  SE , Homann  N , Pauligk  C ,  et al.  Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial.   JAMA Oncol. 2017;3(9):1237-1244. doi:10.1001/jamaoncol.2017.0515PubMedGoogle ScholarCrossref
65.
Terashima  M , Yoshida  K , Rha  SY ,  et al.  International retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-GC-1).   Ann Gastroenterol Surg. Published online October 20, 2021. doi:10.1002/ags3.12515Google ScholarCrossref
66.
Riihimäki  M , Hemminki  A , Sundquist  K , Sundquist  J , Hemminki  K .  Metastatic spread in patients with gastric cancer.   Oncotarget. 2016;7(32):52307-52316. doi:10.18632/oncotarget.10740PubMedGoogle ScholarCrossref
67.
Bonnot  PE , Piessen  G , Kepenekian  V ,  et al; FREGAT and BIG-RENAPE Networks.  Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTO-CHIP study): a propensity score analysis.   J Clin Oncol. 2019;37(23):2028-2040. doi:10.1200/JCO.18.01688PubMedGoogle ScholarCrossref
68.
Yang  X-J , Huang  C-Q , Suo  T ,  et al.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial.   Ann Surg Oncol. 2011;18(6):1575-1581. doi:10.1245/s10434-011-1631-5PubMedGoogle ScholarCrossref
69.
Mezhir  JJ , Shah  MA , Jacks  LM , Brennan  MF , Coit  DG , Strong  VE .  Positive peritoneal cytology in patients with gastric cancer: natural history and outcome of 291 patients.   Ann Surg Oncol. 2010;17(12):3173-3180. doi:10.1245/s10434-010-1183-0PubMedGoogle ScholarCrossref
70.
Badgwell  B , Cormier  JN , Krishnan  S ,  et al.  Does neoadjuvant treatment for gastric cancer patients with positive peritoneal cytology at staging laparoscopy improve survival?   Ann Surg Oncol. 2008;15(10):2684-2691. doi:10.1245/s10434-008-0055-3PubMedGoogle ScholarCrossref
71.
Okabe  H , Ueda  S , Obama  K , Hosogi  H , Sakai  Y .  Induction chemotherapy with S-1 plus cisplatin followed by surgery for treatment of gastric cancer with peritoneal dissemination.   Ann Surg Oncol. 2009;16(12):3227-3236. doi:10.1245/s10434-009-0706-zPubMedGoogle ScholarCrossref
72.
Badgwell  B , Blum  M , Das  P ,  et al.  Phase II trial of laparoscopic hyperthermic intraperitoneal chemoperfusion for peritoneal carcinomatosis or positive peritoneal cytology in patients with gastric adenocarcinoma.   Ann Surg Oncol. 2017;24(11):3338-3344. doi:10.1245/s10434-017-6047-4PubMedGoogle ScholarCrossref
73.
Marutsuka  T , Shimada  S , Shiomori  K ,  et al.  Mechanisms of peritoneal metastasis after operation for non-serosa-invasive gastric carcinoma: an ultrarapid detection system for intraperitoneal free cancer cells and a prophylactic strategy for peritoneal metastasis.   Clin Cancer Res. 2003;9(2):678-685.PubMedGoogle Scholar
74.
Takebayashi  K , Murata  S , Yamamoto  H ,  et al.  Surgery-induced peritoneal cancer cells in patients who have undergone curative gastrectomy for gastric cancer.   Ann Surg Oncol. 2014;21(6):1991-1997. doi:10.1245/s10434-014-3525-9PubMedGoogle ScholarCrossref
75.
Fujitani  K , Yang  H-K , Mizusawa  J ,  et al; REGATTA study investigators.  Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial.   Lancet Oncol. 2016;17(3):309-318. doi:10.1016/S1470-2045(15)00553-7PubMedGoogle ScholarCrossref
76.
Lee  YH , Lee  JW , Jang  HS .  Palliative external beam radiotherapy for the treatment of tumor bleeding in inoperable advanced gastric cancer.   BMC Cancer. 2017;17(1):541. doi:10.1186/s12885-017-3508-xPubMedGoogle ScholarCrossref
77.
Tey  J , Back  MF , Shakespeare  TP ,  et al.  The role of palliative radiation therapy in symptomatic locally advanced gastric cancer.   Int J Radiat Oncol Biol Phys. 2007;67(2):385-388. doi:10.1016/j.ijrobp.2006.08.070PubMedGoogle ScholarCrossref
78.
Jeurnink  SM , van Eijck  CH , Steyerberg  EW , Kuipers  EJ , Siersema  PD .  Stent versus gastrojejunostomy for the palliation of gastric outlet obstruction: a systematic review.   BMC Gastroenterol. 2007;7:18. doi:10.1186/1471-230X-7-18PubMedGoogle ScholarCrossref
79.
Chen  XJ , Chen  GM , Wei  YC ,  et al.  Palliative gastrectomy vs gastrojejunostomy for advanced gastric cancer with outlet obstruction: a propensity score matching analysis.   BMC Cancer. 2021;21(1):188. doi:10.1186/s12885-021-07904-7PubMedGoogle ScholarCrossref
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Close
Close

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close